Immune-mediated hemolytic anemia is a life-threatening autoimmune condition in dogs. Emergency treatment, monitoring, and welfare support through a complex, prolonged disease course are essential.
IMHA presents as a welfare emergency. The rapid destruction of red blood cells causes profound anemia with acute onset of weakness, pallor (white or yellow gums), rapid breathing, and collapse. The disease can deteriorate from mild lethargy to cardiovascular crisis within 24-48 hours. Emergency hospitalization with oxygen supplementation, blood transfusion, and immunosuppressive therapy is the welfare-critical response.
The psychological and physical experience of severe anemia is distressing — tissue hypoxia causes weakness, nausea, and respiratory distress. Providing adequate analgesia for dogs experiencing ischemic pain, minimizing unnecessary stimulation in acute crisis, and offering calm, supportive nursing care all contribute to welfare during hospitalization.
Survivors of acute IMHA face prolonged immunosuppressive therapy tapering over months. Corticosteroid side effects — polyuria, polydipsia, muscle wasting, increased infection risk — require monitoring and management. Relapse is common (20-40%) and requires rapid recognition and treatment. Quality of life between crises is generally good for dogs in remission.